177,500 Shares in Royalty Pharma PLC $RPRX Acquired by Andra AP fonden

Andra AP fonden acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 177,500 shares of the biopharmaceutical company's stock, valued at approximately $8,515,000.

Other large investors have also recently added to or reduced their stakes in the company. Barton Investment Management bought a new stake in shares of Royalty Pharma in the 1st quarter valued at approximately $905,000. Nomura Asset Management Co. Ltd. increased its holdings in Royalty Pharma by 16.2% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 172,418 shares of the biopharmaceutical company's stock worth $6,662,000 after buying an additional 24,048 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Royalty Pharma during the fourth quarter valued at approximately $4,923,000. Qsemble Capital Management LP bought a new position in Royalty Pharma during the fourth quarter valued at approximately $2,875,000. Finally, Thrivent Financial for Lutherans lifted its stake in Royalty Pharma by 10.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 233,320 shares of the biopharmaceutical company's stock valued at $9,016,000 after acquiring an additional 22,015 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

RPRX has been the subject of several analyst reports. UBS Group lifted their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Morgan Stanley increased their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research report on Friday, April 10th. Weiss Ratings lowered Royalty Pharma from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, May 15th. Citigroup boosted their price target on Royalty Pharma from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Finally, TD Cowen upped their price target on Royalty Pharma from $50.00 to $65.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Royalty Pharma presently has an average rating of "Buy" and an average target price of $56.57.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $58.72 on Thursday. Royalty Pharma PLC has a 1 year low of $34.08 and a 1 year high of $59.44. The firm's fifty day simple moving average is $55.37 and its 200 day simple moving average is $49.00. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $33.81 billion, a PE ratio of 39.95, a PEG ratio of 10.35 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.22 by $0.08. The firm had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. On average, sell-side analysts anticipate that Royalty Pharma PLC will post 5.18 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma's dividend payout ratio (DPR) is 63.95%.

Insiders Place Their Bets

In other news, CFO Terrance P. Coyne sold 64,399 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total value of $3,476,258.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares of the company's stock, valued at $10,165,559. This represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 427,800 shares of company stock worth $23,333,723. Corporate insiders own 18.84% of the company's stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.